Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Mycophenolate Mofetil (MMF)
Treatment for Chronic kidney disease due to glomerulonephritis
Typical Dosage: 1-2 g orally twice daily
Effectiveness
78%
Safety Score
35%
Clinical Trials
100
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
1-2 g orally twice daily
Time to Effect
1-3 months
Treatment Duration
1-3 years or more
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$3,000
Monitoring:$800
Side Effect Mgmt:$700
Total Annual:$4,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$6,618
Cost per Remission
$11,250
Comparison vs Cyclophosphamide (maintenance)
Cost Difference
+$500/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Mycophenolate Mofetil (MMF) Outcomes
for Chronic kidney disease due to glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+68%
Remission Rate
+40%
Common Side Effects
Gastrointestinal (diarrhea, nausea)
+30%
Leukopenia/anemia
+15%
Infections
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov